ITGB2 Matched Antibody Pair (651) (APMAB-651LY)

Liu, H., Wang, J., Luo, T., Zhen, Z., Liu, L., Zheng, Y., ... & Hu, X. (2023). Correlation between ITGB2 expression and clinical characterization of glioma and the prognostic significance of its methylation in low-grade glioma (LGG). Frontiers in endocrinology, 13, 1106120.

Xu, H., Zhang, A., Han, X., Li, Y., Zhang, Z., Song, L., ... & Lou, M. (2022). ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. Cancer Immunology, Immunotherapy, 1-16.

Zu, L., He, J., Zhou, N., Zeng, J., Zhu, Y., Tang, Q., ... & Xu, S. (2022). The profile and clinical significance of ITGB2 expression in non-Small-Cell lung cancer. Journal of Clinical Medicine, 11(21), 6421.

Sun, Z., Dang, Q., Liu, Z., Shao, B., Chen, C., Guo, Y., ... & Yuan, W. (2021). LINC01272/miR-876/ITGB2 axis facilitates the metastasis of colorectal cancer via epithelial-mesenchymal transition. Journal of Cancer, 12(13), 3909.

Wei, J., Huang, X. J., Huang, Y., Xiong, M. Y., Yao, X. Y., Huang, Z. N., ... & Cheng, P. (2021). Key immune-related gene ITGB2 as a prognostic signature for acute myeloid leukemia. Annals of Translational Medicine, 9(17).

George, L., Menden, H., Xia, S., Yu, W., Holmes, A., Johnston, J., ... & Sampath, V. (2021). ITGB2 (Integrin β2) immunomodulatory gene variants in premature infants with necrotizing enterocolitis. Journal of pediatric gastroenterology and nutrition, 72(2), e37-e41.

Li, J., Zhang, Z., Feng, X., Shen, Z., Sun, J., Zhang, X., ... & Wang, Z. (2021). Stanniocalcin-2 promotes cell EMT and glycolysis via activating ITGB2/FAK/SOX6 signaling pathway in nasopharyngeal carcinoma. Cell Biology and Toxicology, 1-14.

Yang, M., Qin, Q., Zhu, J., Guo, Y., Yin, T., Wu, H., & Wang, C. (2020). Long noncoding RNA ITGB2‐AS1 promotes growth and metastasis through miR‐4319/RAF1 axis in pancreatic ductal adenocarcinoma. Journal of Cellular Physiology.

Dai, J., Xu, L. J., Han, G. D., Jiang, H. T., Sun, H. L., Zhu, G. T., & Tang, X. M. (2018). Down-regulation of long non-coding RNA ITGB2-AS1 inhibits osteosarcoma proliferation and metastasis by repressing Wnt/β-catenin signalling and predicts favourable prognosis. Artificial cells, nanomedicine, and biotechnology, 46(sup3), 783-790.

Liu, M., Gou, L., Xia, J., Wan, Q., Jiang, Y., Sun, S., ... & Zhang, Y. (2018). LncRNA ITGB2-AS1 could promote the migration and invasion of breast cancer cells through up-regulating ITGB2. International journal of molecular sciences, 19(7), 1866.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Human Anti-ITGB2 Recombinant Antibody (CBXC-0936)

Mouse Anti-ITGB2 Recombinant Antibody (MEM-148)

Mouse Anti-ITGB2 Recombinant Antibody (CBFYC-2838)

Mouse Anti-ITGB2 Recombinant Antibody (CBYY-I0494)

Mouse Anti-ITGB2 Recombinant Antibody (CBYY-I0038)

Rat Anti-ITGB2 Recombinant Antibody (CBFYC-2843)

Mouse Anti-ITGB2 Recombinant Antibody (5F12)

Rat Anti-ITGB2 Recombinant Antibody (CBYY-I0497)

Mouse Anti-ITGB2 Recombinant Antibody (4A118)

Mouse Anti-ITGB2 Recombinant Antibody (3H1050)

Isotype control